Stephens initiated coverage on Thermo Fisher Scientific with an Overweight rating and $680 price target. The firm highlights the company's biopharma expansion, M&A strategy, and key growth areas like CDMO and biologics drug substance production. Latest Ratings for TMO Date Firm Actio...